Single Centre, Prospective, Comparative, Open-Label, Randomised Study to Evaluate the Efficacy and Tolerability of the Combination of Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-Abdominal Abscesses

Trial Profile

Single Centre, Prospective, Comparative, Open-Label, Randomised Study to Evaluate the Efficacy and Tolerability of the Combination of Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-Abdominal Abscesses

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Metronidazole; Moxifloxacin; Piperacillin/tazobactam
  • Indications Bacterial infections; Intra-abdominal infections
  • Focus Therapeutic Use
  • Acronyms MEMO
  • Sponsors Bayer
  • Most Recent Events

    • 21 Jun 2011 Planned End Date changed from 1 Aug 2009 to 1 Aug 2012 as reported by ClinicalTrials.gov.
    • 22 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top